Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer

Research output: Contribution to journalJournal articleResearchpeer-review


BACKGROUND: Definition and treatment options for locally advanced non-resectable pancreatic cancer (LAPC) vary. Treatment options range from palliative chemotherapy to chemoradiotherapy (CRT). Several studies have shown that a number of patients become resectable after complementary treatment prior to surgery. METHODS: From 2001 to 2005, 63 consecutive patients with unresectable LAPC received CRT. CRT was given at a dose of 50 Gy/27 fractions, combined with UFT (300 mg/m(2)/day) and folinic acid. Re-evaluation of resectability was planned 4-6 weeks after completion of CRT. RESULTS: Fifty-eight patients completed all 27 treatment fractions. Toxicity was generally mild, with 18 patients experiencing CTCAE grade 3 or worse acute reactions. One patient died following a treatment-related infection. Two patients developed grade 4 upper GI bleeding. Median survival was 10.6 (8-13) months. Eleven patients underwent resection, leading to a resection rate of 17%, and a median survival of 46 (23-nr) months. All 11 patients had a R0 resection. Median survival for the patients not resected was 8.8 (8-12) months. CONCLUSION: CRT with 50 Gy combined with UFT, is a well-tolerated and effective treatment for patients with LAPC. R0 resection was possible in 17% leading to a long median survival of 46 months in resected patients.
Original languageEnglish
JournalRadiotherapy & Oncology
Issue number2
Pages (from-to)226-30
Publication statusPublished - 1. Aug 2009


  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms
  • Tegafur
  • Uracil


Dive into the research topics of 'Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this